Literature DB >> 3451881

Pharmacological influence of specific bradycardic agents on the pacemaker current of sheep cardiac Purkinje fibres. A comparison between three different molecules.

P P Van Bogaert1, M Goethals.   

Abstract

The diastolic depolarization rate of isolated sheep Purkinje fibres was reduced in the presence of micromolar concentrations of the 'specific bradycardic agent' falipamil (AQ-A39) and its congener UL-FS49. Both drugs reduced the amount of pacemaker current, if, activated during the diastolic depolarization phase. The if activation curve was reduced in amplitude but not shifted. UL-FS49 was more effective compared to falipamil in causing this reduction of if amplitude at similar concentrations. The reduction of the if amplitude was presumably caused by a drug-induced decrease in if current conductance. This if current block showed use-dependence. With UL-FS49 less and less if was activated with every successive voltage clamp pulse of a train, with little recovery of if block after a rest interval. Use-dependent block was smaller with comparable falipamil concentrations but full recovery was observed after a rest interval. No use-dependent block was observed with alinidine, a drug which also causes reduction of if by shifting its activation range to more negative potentials. These results indicate that the reduction of pacemaker current observed with two different types of 'specific bradycardic agents' is obtained by different mechanisms.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3451881     DOI: 10.1093/eurheartj/8.suppl_l.35

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  9 in total

1.  HCN2 channels: a permanent open state and conductance changes.

Authors:  François Pittoors; Pierre Paul Van Bogaert
Journal:  J Membr Biol       Date:  2014-11-13       Impact factor: 1.843

2.  Direct inhibition of the pacemaker (If) current in rabbit sinoatrial node cells by genistein.

Authors:  Claudia Altomare; Agnese Tognati; Jocelyn Bescond; Arnaldo Ferroni; Mirko Baruscotti
Journal:  Br J Pharmacol       Date:  2006-01       Impact factor: 8.739

3.  Electrophysiological effects of S 16257, a novel sino-atrial node modulator, on rabbit and guinea-pig cardiac preparations: comparison with UL-FS 49.

Authors:  C Thollon; C Cambarrat; J Vian; J F Prost; J L Peglion; J P Vilaine
Journal:  Br J Pharmacol       Date:  1994-05       Impact factor: 8.739

4.  On the mechanism of the "specific bradycardic action" of the verapamil derivative UL-FS 49.

Authors:  T Doerr; W Trautwein
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-04       Impact factor: 3.000

5.  Effects of the bradycardic agent ZD 7288 on membrane voltage and pacemaker current in sheep cardiac Purkinje fibres.

Authors:  F Berger; U Borchard; R Gelhaar; D Hafner; T Weis
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-12       Impact factor: 3.000

6.  Inhibitory actions of ZENECA ZD7288 on whole-cell hyperpolarization activated inward current (If) in guinea-pig dissociated sinoatrial node cells.

Authors:  R E BoSmith; I Briggs; N C Sturgess
Journal:  Br J Pharmacol       Date:  1993-09       Impact factor: 8.739

7.  Some properties of the UL-FS 49 block of the hyperpolarization-activated current (i(f)) in sino-atrial node myocytes.

Authors:  D DiFrancesco
Journal:  Pflugers Arch       Date:  1994-05       Impact factor: 3.657

8.  Electropharmacology of the bradycardic agents alinidine and zatebradine (UL-FS 49) in a conscious canine ventricular arrhythmia model of permanent coronary artery occlusion.

Authors:  I Aidonidis; J Brachmann; I Rizos; A Zacharoulis; I Stavridis; P Toutouzas; W Kübler
Journal:  Cardiovasc Drugs Ther       Date:  1995-08       Impact factor: 3.727

9.  Population Pharmacokinetic Data Analysis of Cilobradine, an I f Channel Blocker.

Authors:  Gabriele Fliss; Alexander Staab; Christiane Tillmann; Dirk Trommeshauser; Hans G Schaefer; Charlotte Kloft
Journal:  Pharm Res       Date:  2007-06-21       Impact factor: 4.200

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.